

Curriculum vitae

Date Prepared: 02/06/2013
Name: Roger Bedimo
Office Address: 4500 South Lancaster Road, 111-D
Dallas, Texas 75216
Work Phone: 214-857-0397
Work E-Mail: Roger.bedimo@va.gov
Work Fax: 214-302-1433
Place of Birth: Douala, Cameroon



Handwritten signature and date: 1/8/13

Education

Year	Degree (Honors)	Field of Study (Thesis advisor for PhDs)	Institution
09/83 to 11/89	MD (Hon.)	Medicine	University Center for Health Sciences University of Yaoundé, Cameroon
09/93 to 05/97	MS	Parasitology	Tulane University Graduate School New Orleans, Louisiana

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline (Lab PI for postdoc research)	Institution
07/98 to 06/01	Resident	Internal Medicine	Wright State University Medical School, Dayton, Ohio
07/00 to 06/01	Chief Resident	Internal Medicine	Wright State University Internal Medicine /Dayton VA Medical Center
07/01 to 06/03	Fellow	Infectious Diseases	University of Alabama at Birmingham, Birmingham, Alabama

Current Licensure and Certification

Licensure
Alabama
Ohio

Board and Other Certification

- 2001 Diplomate, American Board of Internal Medicine
- 2003 Diplomate in Infectious Diseases, ABIM
- 2011 Recertification in Internal Medicine, ABIM

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
2001	Alpha Omega Alpha	AOA Epsilon Chapter, Wright State University
2001	Resident of the Year	Wright State University
2001	Teacher of the Year	Wright State University
2007	Fellow	American College of Physicians

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
2003-2010	Assistant Professor	Medicine	University of Texas Southwestern
2010-present	Associate Professor	Medicine	University of Texas Southwestern
2005-present	Director, Infectious Diseases Fellowship Training Program	Medicine	University of Texas Southwestern

Appointments at Hospitals/Affiliated Institutions

<u>Past</u>			
Year(s)	Position Title	Department/Division	Institution
1990-1993	District Chief of Public Health		Ministry of Public Health, Cameroon
1996-1998	Project Coordinator	Medicine/HIV Program Office	LSU Medical Center, New Orleans, Louisiana
2003-2005	Director, HIV Program	Medicine/Infectious Diseases	VA North Texas Health Care System, Dallas, Texas
<u>Current</u>			
Year(s)	Position Title	Department/Division	Institution
2005-present	Section Chief, Infectious Diseases	Medicine/Infectious Diseases	VA North Texas Health Care System, Dallas, Texas

Other Professional Positions

Year(s)	Position Title	Institution
2010-present	AIDS Clinical Trials Group Clinical Research Site (CRS) Leader	Trinity Health and Wellness Center, Dallas, Texas

Major Administrative/Leadership Positions

Year(s)	Position Title	Institution
2006-present	Course Director, UTSW Annual HIV Update Course and Annual ICAAC/CROI Review	UT Southwestern Medical Center
2005-present	Course Director, Tropical Medicine Senior Elective	UT Southwestern Medical Center
2005-present	Course Director, Infectious Disease Senior Elective	UT Southwestern Medical Center

Committee Service *(Member, unless noted otherwise)*

Year(s)	Name of Committee	Institution/Organization
<u>UTSW</u>		
2006-	Continuous Medical Education Committee	UT Southwestern Medical Center
2011-	Infectious Diseases Division Chief Search Committee	UT Southwestern Medical Center
<u>Hospital</u>		
2006-	Continuous Medical Education Committee	VA North Texas Health Care System
2008-2008	Chair, Continuous Medical Education Committee	VA North Texas Health Care System
<u>State/Regional</u>		
None		
<u>National/International</u>		
2007-present	Core Faculty Member Member of "Cases On the Web (COW)" Editorial Board	International Antiviral Society – USA
2010-present	Member, Program Committee	HIV Medicine Association (HIVMA) Minority Clinical Fellowship
2011-present	Board of Directors	American Conference for the Treatment of HIV (ACT HIV)
2008-2010	Treasurer, Executive Committee	VA Specialty Providers in Infectious Diseases (VASPID)
2010-2012	Secretary, Executive Committee	VASPID
2012-present	Vice-President, Executive Committee	VASPID

Professional Societies

Dates	Society Name, member
2006-present	Member, International AIDS Society – USA
2001-present	Member, The Infectious Disease Society of America

1999-present	Member, The American Medical Association
1998-present	Member, The American College of Physicians
1994-present	Member, The American Society of Tropical Medicine and Hygiene
1994-present	Member, The Royal Society of Tropical Medicine and Hygiene
2007-present	Fellow, the American College of Physicians

Grant Review Activities

Year(s)	Name of Review Committee	Organization
2009-present	Ad-hoc reviewer, CFAR Grants	University of Pennsylvania's Center for AIDS Research

Editorial Activities

Year(s)	Journal Name
<u>Editor/Associate Editor</u>	
None	
<u>Editorial Board</u>	
None	
<u>Ad Hoc Reviewer</u>	
	AIDS, Journal of AIDS, HIV Medicine, Clinical Infectious Diseases

Grant Support

Present Grant Support	
	Grantor: Veterans Health Administration (MERIT grant I01 CX000418-01A1)
	Title of Project: Rates and determinants of decreased bone health among HIV-infected patients
	Role: Principal Investigator
	Grant Period: 2011-2015
	Annual Amount and date (direct costs only): \$150,000 (April 2011)
	Total Amount of award (if multi-year) and dates (direct costs only): \$600,000 (2011-2015)
	Grantor: National Institutes of Health (NIAID) - R03 AG039689
	Title of Project: Using VA registry data to estimate age-related risk trajectories for HIV patients.
	Role: Co-investigator (Song Zhang, PhD)
	Grant Period: 2012-2014
	Annual Amount and date (direct costs only): \$ 50,000
	Total Amount of award (if multi-year) and dates (direct costs only): \$ 100,000
	Grantor: Veterans Health Administration and Office of Information Technology

	Grantor: National Institutes of Health (NIAID) - U01 AI069471
	Title of Project: AIDS Clinical Trials Unit
	Role: Site Investigator – Clinical Research Site Leader
	Grant Period: 2012-2013
	Annual Amount and date (direct costs only): \$237,766
	Total Amount of award (if multi-year) and dates (direct costs only): \$237,766
	Grantor: National Institutes of Health (NIAAA) - 52U10 AA13566
	Title of Project: Veterans Aging Cohort Study (VACS) / Consortium to improve Outcomes in hiv/AIDS, Alcohol, Aging, and multi-Substance use (COMpAAAS)
	Role: Site Investigator
	Grant Period: 2012-2017
	Annual Amount and date (direct costs only): \$ 192,275
	Total Amount of award (if multi-year) and dates (direct costs only): \$ 992,275

Past Grant and Contract Support	
	Title of Project: Prototype Software for Creating Custom Reports from VistA for Infectious Diseases
	Role: Principal Investigator
	Grant Period: 2011-2012
	Annual Amount and date (direct costs only): \$426,200
	Total Amount of award (if multi-year) and dates (direct costs only): \$426,200
	Grantor: Merck Pharmaceuticals
	Title of Project: Evaluation of Safety and Efficacy of Raltegravir and Darunavir Combination in Antiretroviral-Naïve Patients
	Role: Principal Investigator
	Grant Period: 2009-2011
	Annual Amount and date (direct costs only): \$177,198
	Total Amount of award (if multi-year) and dates (direct costs only): \$354,396
	Grantor: Tibotec Therapeutics
	Title of Project: Evaluation of Safety and Efficacy of Raltegravir and Darunavir Combination in Antiretroviral-Naïve Patients
	Role: Principal Investigator
	Grant Period: 2009-2011
	Annual Amount and date (direct costs only): \$68,655
	Total Amount of award (if multi-year) and dates (direct costs only): \$205,967
	Grantor: Federal Drug Administration
	Title of Project: Impact of Antiretroviral Therapy on Cardiovascular Disease Risk among HIV-Infected Patients
	Role: Principal Investigator

	Grant Period: 2011-2012
	Annual Amount and date (direct costs only): \$59,136
	Total Amount of award (if multi-year) and dates (direct costs only): \$59,136
	Grantor: Abbott Virology
	Title of Project: Evaluation of Antiretroviral Regimen Durability in Clinical Setting
	Role: Principal Investigator
	Grant Period: 2008
	Annual Amount and date (direct costs only): \$47,500
	Total Amount of award (if multi-year) and dates (direct costs only): \$47,500
	Grantor: Merck Pharmaceuticals
	Title of Project: A Study to Evaluate 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults
	Role: Site Investigator
	Grant Period: 2007
	Annual Amount and date (direct costs only): \$55,000
	Total Amount of award (if multi-year) and dates (direct costs only): \$55,000
	Grantor: Bristol Myers Squibb Virology
	Title of Project: Bone Mineral Density Changes in HIV-Infected Women
	Role: Co-Investigator
	Grant Period: 2006
	Annual Amount and date (direct costs only): \$202,650
	Total Amount of award (if multi-year) and dates (direct costs only): \$202,650

Invited Lectures

Year(s)	Title	Location
<u>International</u>		
2005	Update on Sexually Transmitted Diseases	Mexican Academy of Clinical Pathology National Meeting Monterrey, Mexico
2007	Treatment Strategies for Drug-Resistant HIV Infection	University of Nuevo Leon Monterrey, Mexico
2008	Non-AIDS-Defining Malignancies Among HIV-Infected Patients	University of Nuevo Leon Monterrey, Mexico
<u>National</u>		
2005	Update on HIV Disease in Africa	American Academy of Physician Assistants Annual Meeting Orlando, Florida
2006	HIV-Associated Metabolic Abnormalities	American Academy of Physician

		Assistants Annual Meeting San Francisco, California
2008	Non-AIDS Defining Malignancies Among HIV-Infected Patients	Tulane University New Orleans, Louisiana
2009	Invasive Candida Infections	St. Michael's Hospital Newark, New Jersey
2009	Class-Sparing Antiretroviral Regimens	Merck Expert Input Forum Indianapolis, Indiana
2009	Cancers in HIV	American Conference for the Treatment of HIV (ACT HIV) Denver, Colorado
2009	Cardiovascular Complications of HIV Disease and Antiretroviral Therapy	University of North Carolina at Chapel Hill, North Carolina
2010	Non-AIDS-Defining Malignancies Among HIV-Infected Patients	American Conference for the Treatment of HIV (ACT HIV) Denver, Colorado
2010	Chronic Inflammation in HIV Disease	Merck Expert Input Forum Dallas, Texas
2011	Non-AIDS-Defining Malignancies Among HIV-Infected Patients	American Conference for the Treatment of HIV (ACT HIV) Denver, Colorado
2012	Evaluation and Management of Bone Disease in HIV-Infected Patients	American Conference for the Treatment of HIV (ACT HIV) Denver, Colorado
2013	Will HIV-Infected Patients Make Old Bones?: Fracture Risk in HIV Disease; Impact of HAART and HCV Co-Infection	Washington University School of Medicine, St. Louis, Missouri.
<u>Regional/Local</u>		
2005	Skin, Soft Tissue, Bone and Joint Infections	UT Southwestern Update in Internal Medicine, Dallas, TX
2009	Skin and Soft Tissue Infections in the Era of MRSA	Southern Medical Society Meeting Dallas, TX
2010	HIV, HAART and the Heart	UTS Southwestern Internal Medicine Grand Rounds
2011	HIV Update from the Conference on Retroviruses and Opportunistic Infections	UT Southwestern Medical Center Dallas, TX
2011	Metabolic Complications of HIV Disease	Methodist Hospital Grand Rounds Dallas, TX
2011	Metabolic Complications of HIV Disease	Presbyterian Hospital Grand Rounds Dallas, TX
2011	Will HIV-Infected Patients Make Old Bones?	UT Southwestern Internal Medicine Grand Rounds
2012	Selective Pressure of Malaria on Human	UT Southwestern Global Health

Technological and Other Scientific Innovations

None

Service to the Community

Member, Mentoring Committee of the C.V. Roman Medical Society, DFW Chapter of the National Medical Association.

Bibliography

Peer-Reviewed Publications

Original Research Articles

1. Cohen DA, Farley TA, **Bedimo R.** *et al.* Cost as a barrier to condom use: the evidence for condom subsidies in the United States. *Am J Public Health.* 1999;89:567-568
2. Cohen DA, Nsuami M, **Bedimo R** *et al.* a school-based chlamydia control program using DNA amplification technology. *Pediatrics.* 1998;101:1
3. Cohen DA, Farley TA, **Bedimo JR** *et al.* Implementation of a condom social marketing in Louisiana, 1993 to 1996. *Am J Public Health.* 1999;89:204-208
4. Bahebeck J, **Bedimo R**, Eyenga V, Kouamfack C, Kingue T, Nierenet M, Sosso M.. The management of musculoskeletal infection in HIV carriers. *Acta Orthopædica Belgica.* 2004;70(4):355-60
5. **Bedimo R**, Chen R, Accort N, *et al.* Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989 to 2002. *Clin Infect Dis.* 2004 Nov 1;39(9):1380-4.
6. Marinella MA, Burdette SD, **Bedimo R**, Markert RJ. Leukemoid reactions complicating colitis due to *Clostridium difficile*. *South Med J.* 2004 Oct;97(10):959-63.
7. **Bedimo R**, Hoesley C, Saag M. Non-AIDS-defining malignancies in the HAART era. Reply to Dal Maso *et al.* *Clin Infect Dis.* 2005 Jul 1;41(1):126-127.
8. **Bedimo R**, Chen R, Westfall A, Raper J, Allison J and Saag, M. Sustained HIV viral suppression following treatment interruption: an observational study. *AIDS Research and Human Retroviruses.* 2006 Jan;22(1):40-4.
9. **Bedimo R**, Ghurani R, Nsuami M, Turner D, Kvanli M, Brown G, and Margolis D. Lipid abnormalities in HIV/HCV co-infected patients. *HIV Medicine,* 2006 Nov;7(8):530-6.
10. Kaur R, **Bedimo R**, Kvanli M, Turner D, Shaw L, and Margolis D. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. *AIDS Research and Therapy* 2006 May 26;3(1):16.
11. Busti AJ, **Bedimo R**, Margolis D, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir/ritonavir (ATV/RTV): A prospective study using hyperinsulinemic, euglycemic clamp testing. *Antiv Ther* 2006;11:L37.
12. Cenizal MJ, Skiest D, Lubner S, **Bedimo R**, Davis P, Fox P, Delaney K, Hardy RD. A prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high MRSA prevalence. *Antimicrobial Agents and Chemotherapy* 2007 Jul;51(7):2628-30.

13. Morpeth S, Murdoch D, Cabell C, Karchmer A, Pappas P, Levine D, Nacinovich F, Tattevin P, MD; Fernández-Hidalgo N, Dickerman S, Bouza E, del Rio A, Lejko-Zupanc T, de Oliveira A, Iarussi D, Klein J, Chirouze C, **Bedimo R**, Corey R, Fowler V, and the ICE-PCS Investigators. Non-HACEK* gram-negative bacilli endocarditis: Observations from the International Collaboration on Endocarditis. *Annals of Internal Medicine*. 18 December 2007;147(12):829-835
14. Chastain LM, Bain AM, Edwards KL, **Bedimo R**, Busti AJ. A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. *Journal of Clinical Lipidology*. 2007;1: 634–639
15. Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, **Bedimo R**, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ. The lipid lowering efficacy and safety after a switch to an atazanavir/ritonavir based HAART in HIV-infected patients: a multi-center retrospective study. *Pharmacotherapy*. 2008 Mar;28(3):323-30.
16. Rahman AP, Eaton SA, Nguyen, S, Bain AM, Payne K, **Bedimo R.**, and Busti AJ. The safety and efficacy of simvastatin in treating hyperlipidemia in HIV-infected patients on efavirenz-based HAART. *Pharmacotherapy* 2008;28(3):323–330
17. Bain AM, Payne KD, Rahman AP, **Bedimo R**, McClayton D, Rodriguez-Barradas M, and Busti AJ. The lipid-lowering efficacy of switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients. *American Journal of Infectious Diseases* 2008;4 (2): 147-151
18. Nguyen ST, Bain AM, **Bedimo R**, Hall RG, Busti AJ. Acute elevation of triglycerides after initiation of fosamprenavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. *J Clin Lipidol*. 2008 Oct;2(5):398-400. Epub 2008 Jun 26.
19. Busti AJ, **Bedimo R**, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. *J Investig Med*. 2008 Feb;56(2):539-44
20. Busti AJ, Bain AM, Hall RG 2nd, **Bedimo RJ**, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. *J Cardiovasc Pharmacol*. 2008 Jun;51(6):605-10.
21. Hall RG, Payne K, Bain AM, Rahman A, Nguyen S, Eaton SA, and **Bedimo R**. Multicenter evaluation of vancomycin dosing – emphasis on obesity. *Am J Med*. 2008 Jun;121(6):515-8.
22. **Bedimo, RJ**. Body-fat abnormalities in patients with HIV: Progress and challenges. *Journal of the International Association of Physicians in AIDS Care (JIAPAC)* 2008 Nov-Dec;7(6):292-305.
23. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH; International Collaboration on Endocarditis-Pro prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Pro prospective Cohort Study. *Arch Intern Med*. 2009 Mar 9;169(5):463-73
24. Benito N, Miró JM, de Lazzari E, Cabell CH, del Río A, Altclas J, Commerford P, Delahaye F, Dragulescu S, Giamarellou H, Habib G, Kamarulzaman A, Kumar AS, Nacinovich FM, Suter F, Tribouilloy C, Venugopal K, Moreno A, Fowler VG Jr; ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) Investigators. Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. *Ann Intern Med*. 2009 May 5;150(9):586-94.
25. Betts FR, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, **Bedimo RJ**, Herbrecht R, Ruiz-Palacios G, Young JH, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, and Kartsonis NA, for the Caspofungin High-Dose study Group. A multicenter, double-blind trial of a high-dose

- casposfungin regimen versus a standard casposfungin regimen in adult patients with invasive candidiasis. *Clinical Infectious Diseases*. 2009 Jun 15;48(12):1676-84.
26. **Bedimo RJ**, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected vs. non-infected veterans in the HAART era: Impact of immunosuppression. *Journal of Acquired Immune Deficiency Syndromes*. 2009;52:203-208.
 27. **Bedimo R**, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med* 2010,11:462-468.
 28. **Bedimo R**, Westfall A, Drechsler H, Vidiella G, Tebas P. Abacavir use and Risk of Acute Myocardial Infarction and Cerebrovascular Disease in the HAART era. *Clin Infect Dis* 2011 Jul;53(1):84-91. PMID: 21653308
 29. Triant VA, Josephson F, Rochester CG, Althoff K, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin C, Williams PL, Hughes S, Post W, Chandra-Strobos N, Guaraldi G, Young S, Obenchain R, **Bedimo R**, Miller V, Strobos J. Adverse Outcome Analyses of Observational Data: Interpretation for Clinical Decision-Making. *Clin Infect Dis*. 2012 Feb;54(3):408-13. PMID: 22095570
 30. **Bedimo R**, Kyriakides, T, Brown S, Weidler J, Lie Y, Coakley E, and Holodniy M. Predictive Value of HIV-1 *pol* Replication Capacity and Phenotypic Susceptibility Scores in Antiretroviral Treatment Experienced Patients. *HIV Medicine* 2012. Jul;13(6):345-51. PMID: 22276745
 31. **Bedimo R**, Zhang S, Drechsler H, Maalouf N, and Tebas P. Osteoporotic Fracture Risk Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents. *AIDS*. 2012.Apr 24;26(7):825-31. PMID: 22301411
 32. Hall RG, Giuliano, CA, Haase KK, Thompson, KA, Frei, CR, Forcade, NA, Brouse SA, Bell T, **Bedimo R**, and Alvarez CA. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant *Staphylococcus aureus* bacteremia: a retrospective cohort study. *BMC Infectious Diseases*. 2012, 12:104.
 33. Hall RG, Hazlewood KA, Brouse SD, Giuliano CA, Haase KK, Frei, CR, Forcade, NA, Bell T, **Bedimo R**, and Alvarez CA. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: a retrospective cohort study. *BMC Pharmacology and Toxicology*. In press.

Reviews, Chapters, Monographs and Editorials

1. **Bedimo R** and Skiest D. Fungal Infections of the Central Nervous System. In Goodkin K, Verma A, Shapshak P (eds.): The Spectrum of neuro-AIDS disorders: pathophysiology, diagnosis, and treatment. American Society for Microbiology (ASM) Press, Washington, DC. 2008.
2. **Bedimo R**. Non-AIDS-defining malignancies among HIV-infected patients in the HAART era *Current HIV/AIDS Reports*. 2008. Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9. PMID: 18627663
3. **Bedimo R**. Growth hormone and Tesamorelin in the management of HIV-associated lipodystrophy. *HIV/AIDS - Research and Palliative Care*. HIV AIDS (Auckl). 2011;3:69-79. Epub 2011 Jul. PMID: 22096409
4. **Bedimo, R**. HIV Vaccine Development at the Turn of the 21st Century. *The Federal Practitioner*. In press.

Books/Textbooks

None

Case Reports

1. **Bedimo R**, Weinstein J. Photo quiz. Disseminated blastomycosis. *Clin Infect Dis* 2001;33:1706, 1770-1.
2. **Bedimo R**, Weinstein J. Recurrent extraintestinal *Clostridium difficile* infection *Am J Med* 2003;114(9): 770-1.
3. **Bedimo R**, Geisler W. Dilantin hypersensitivity syndrome masquerading as fever and systemic illness of unknown origin in an HIV-infected patient. *International Journal of STD & AIDS*. 2005 Feb;16(2):178-9.
4. Bridges D, **Bedimo R**. Severe tuberculosis sepsis in an immunocompetent patient. *The American Journal of Medicine*. 2006 Mar;119(3):e11-4.

Letters to the Editor

None

Proceedings of Meetings

1. Mustafa M, **Bedimo R**, and Usman N. Leukemic Infiltration Of The Colon Or Leukemia Associated Inflammatory Bowel Disease? Poster presentation. ACP Ohio Chapter meeting. Columbus 11/05/99
2. **Bedimo R**, Westfall, A, Chen Y, et al., Sustained HIV Viral Suppression Following Treatment Interruption: An Observational Study. Oral Presentation. IDSA 2003 Abstract #109
3. **Bedimo R**, Accort N, Saag M, et al., Trends in AIDS-Defining and other HIV-Associated Malignancies Among HIV-Infected Patients: 1989 to 2002. Poster presentation. IDSA 2003 Abstract #638
4. **Bedimo R**, Ghurani R, Turner D *et al*. Lipid Abnormalities In HIV/HCV Co-Infected Patients. IDSA 2004 Abstract #866
5. Busti AJ, **Bedimo R**, Margolis D, Hardin D. Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Patients After Switch to Atazanavir/Ritonavir (ATV/RTV): A Prospective Study Using Hyperinsulinemic, Euglycemic Clamp Testing. Conference on Adverse Drug Reactions and Lipodystrophy, San Francisco, CA, September 2006.
6. **Bedimo R**, Dunlap M, McGinnis K. A., Rodriguez-Barradas M, Justice A. C. Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Vs. Non-Infected Veterans in The HAART Era: Impact of Immunosuppression. ICCAC 2007, Abstract H-1721; Chicago, IL, September 17-20, 2007
7. **Bedimo R**, Westfall A, Mugavero M, Khanna N, and Saag M. HCV is an independent risk factor for Acute Myocardial Infarction among HIV-infected Veterans. Conference on Retroviruses and Opportunistic Infections, Abstract P-212; Boston, MA, February 3-6, 2008
8. **Bedimo R**, Drechsler H, Pasley M, Woodward W, and Holodniy M. Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz. Abstract P9. 9th International Congress on Drug Therapy in HIV Infection; Glasgow, UK, November 9-13, 2008.
9. **Bedimo R** et al. HCV co-infection and risk of acute myocardial and cerebrovascular disease among HIV-infected patients in the pre-HAART and HAART eras. XVII International AIDS Conference, Mexico City, abstract THAB0205, 2008.
10. **Bedimo R**, et al. Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Vs. Non-Infected Veterans in The HAART Era: Impact of Immunosuppression. XVII International AIDS Conference, Mexico City, Abstract MOPE0243

11. Betts R, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, **Bedimo R**, et al. A Multicenter, Double-Blind Trial of a Higher Caspofungin Dose (hCAS) versus Standard Caspofungin Dose (sCAS) in the Treatment (Rx) of Invasive Candidiasis (IC). ICAAC/IDSA 2008, Abstract M-1847; Washington, DC, October 24-24, 2008.
12. **Bedimo R**, Westfall A, Drechsler H, Tebas P. Abacavir use and Risk of Acute Myocardial Infarction and Cerebrovascular Disease in the HAART era. In: *5th IAS Conference on HIV Pathogenesis, Treatment and Prevention*. Cape Town, South Africa; 2009.
13. **Bedimo R**, Westfall A, Drechsler H, Maalouf N. HCV co-infection is associated with a high risk of osteoporotic fractures among HIV-infected patients. In: *18th International AIDS Conference*. Vienna, Austria: Abstract TUAB0104; 2010.
14. Drechsler H, **Bedimo R**. Currently Preferred ART Regimens Lead to Greater CD4 Gains in US Veterans – In Part Independent of Viral Load Impact. In: *18th International AIDS Conference*. Vienna, Austria: Abstract THPE0114; 2010
15. Hall II R, Hazlewood KA, Brouse SD, Giuliano CA, Haase KK, Frei CR, Forcade NA, Bell T, **Bedimo R**. A multi-center study evaluating the impact of IDSA guideline recommended empiric dosing of vancomycin on nephrotoxicity. In: *48th Infectious Diseases Society of America Conference*. Vancouver, Canada; 2010. Abstract 288.
16. **Bedimo R**, Zhang S, Drechsler H, Tebas P, and Maalouf N. Osteoporotic Fracture Risk Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents. *6th IAS Conference on HIV Pathogenesis, Treatment and Prevention*. Rome, Italy; 2011
17. **Bedimo R**, Drechsler H, Turner D. et al. RADAR Study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as Tenofovir/Emtricitabine combined with boosted Darunavir in antiretroviral-naïve patients. *6th IAS Conference on HIV Pathogenesis, Treatment and Prevention*. Rome, Italy; 2011. Abstract MOPE 214.
18. Drechsler H, Zhang S, Holodniy M, and **Bedimo R**. Immune reconstitution after starting HAART defines survival in US-veterans. *19th International AIDS Conference*. Washington, D.C. Abstract MOPE0113; 2012.
19. Kengne FG, Drechsler H, Maalouf NM, and **Bedimo R**. Hyponatremia Associates with Mortality in Virologically Suppressed HIV Infected Patients. *American Society of Nephrology Annual Conference*. 2012. Abstract 5917.
20. Washington S, Duquaine S, **Bedimo R**, and Kelly K. Efficacy of Atorvastatin, Pravastatin, and Rosuvastatin in HIV Patients on Protease Inhibitors Vs. Patients On NNRTI's. *50th Infectious Diseases Society of America Annual Conference*. San Diego 2012.
21. Drechsler H, Maalouf N, Zhang S, Cutrell B, and **Bedimo R**. Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART. *20th Conference on Retroviruses and Opportunistic Infections*, Abstract R-260; Atlanta, GA, March 3-6, 2013

Clinical Practice Guidelines

None

Non-peer reviewed scientific or medical publications/materials in print or other media

1. **Bedimo R**. HIV-associated metabolic complications; International AIDS Society – USA Cases On the Web; <http://www.iasusa.org/cow/cow-instructions.php?cowid=72> (last updated 06/2011)
2. **Bedimo R**. Non-AIDS-defining cancers in patients with HIV infection. International AIDS Society – USA Cases On the Web; <http://www.iasusa.org/cow/cow-instructions.php?cowid=124>